The Importance of SOCS1 - 1478 CA/del Polymorphism and Expression in Breast Cancer: a Case-control Study in the North of Iran

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 2023 Aug 1

PMID 37526791

Authors

Habibbullah Paeiz

Zivar Salehi

Farhad Mashayekhi

Hamid Saeidi Saedi

Laleh Mirzanejad

Affiliations

Soon will be listed here.

Abstract

Purpose: This project aimed to evaluate the relationship between the suppressor of cytokine signaling-1 (SOCS1) - 1478 CA > del genetic variation and breast cancer susceptibility. Moreover, we investigated the SOCS1 mRNA expression level in cancerous tissues.

Methods: A total of 100 patients with breast cancer and 120 healthy individuals were selected. Genomic DNA was extracted from blood. SOCS1 genotyping and relative gene expression were performed using ARMS-PCR (Amplification-Refractory Mutation System-Polymerase Chain Reaction) and real-time PCR, respectively.

Results: In breast cancer patients, the prevalence of genotype frequencies of SOCS1 (- 1478 CA > del) CA/CA, CA/del, and del/del was 52, 31, and 17%, respectively. Among controls, the distribution of CA/CA, CA/del, and del/del was 63, 15, and 22%, respectively. The chi-square test reported that a significant difference was observed in the genotypic distribution of SOCS1 (- 1478 CA > del) polymorphism between cases and controls (χ = 8.08, P = 0.01). In addition, the presence of the CA/del genotype was associated with an elevated risk of breast cancer (in the codominant model: OR 2.51; 95% CI 1.27-4.96, P = 0.007 and in the over dominant model: OR 2.54; 95% CI 1.32-4.90, P = 0.005). However, there was no significant difference in allelic distributions between the groups (P > 0.05). There was no significant difference in the breast cancer risk associated with the dominant and recessive genetic models when the reference was CA/CA and CA/CA + CA/del genotype, respectively (P = 0.09 and P = 0.38). Moreover, the expression of SOCS1 decreased in cancerous tissues as compared to the adjacent non-cancerous tissues (P < 0.0001).

Conclusion: In conclusion, a functional SOCS1 promoter polymorphism (- 1478 CA > del) may affect breast cancer susceptibility.

Citing Articles

SOCS1 is a critical checkpoint in immune homeostasis, inflammation and tumor immunity.

Bidgood G, Keating N, Doggett K, Nicholson S Front Immunol. 2024; 15:1419951.

PMID: 38947335 PMC: 11211259. DOI: 10.3389/fimmu.2024.1419951.

References

Tosello G, Torloni M, Mota B, Neeman T, Riera R . Breast surgery for metastatic breast cancer. Cochrane Database Syst Rev. 2018; 3:CD011276. PMC: 6494198. DOI: 10.1002/14651858.CD011276.pub2. View

Marzbani B, Nazari J, Najafi F, Marzbani B, Shahabadi S, Amini M . Dietary patterns, nutrition, and risk of breast cancer: a case-control study in the west of Iran. Epidemiol Health. 2019; 41:e2019003. PMC: 6446065. DOI: 10.4178/epih.e2019003. View

Antoniou A, Easton D . Models of genetic susceptibility to breast cancer. Oncogene. 2006; 25(43):5898-905. DOI: 10.1038/sj.onc.1209879. View

Rojas K, Stuckey A . Breast Cancer Epidemiology and Risk Factors. Clin Obstet Gynecol. 2016; 59(4):651-672. DOI: 10.1097/GRF.0000000000000239. View

Provenzano E, Ulaner G, Chin S . Molecular Classification of Breast Cancer. PET Clin. 2018; 13(3):325-338. DOI: 10.1016/j.cpet.2018.02.004. View

Wendt C, Margolin S . Identifying breast cancer susceptibility genes - a review of the genetic background in familial breast cancer. Acta Oncol. 2019; 58(2):135-146. DOI: 10.1080/0284186X.2018.1529428. View

Inagaki-Ohara K, Kondo T, Ito M, Yoshimura A . SOCS, inflammation, and cancer. JAKSTAT. 2013; 2(3):e24053. PMC: 3772102. DOI: 10.4161/jkst.24053. View

Ying J, Qiu X, Lu Y, Zhang M . SOCS1 and its Potential Clinical Role in Tumor. Pathol Oncol Res. 2019; 25(4):1295-1301. DOI: 10.1007/s12253-019-00612-5. View

Qian Q, Lv Y, Li P . SOCS1 is associated with clinical progression and acts as an oncogenic role in triple-negative breast cancer. IUBMB Life. 2018; 70(4):320-327. DOI: 10.1002/iub.1728. View

10.

Qiu L, Xu K, Liang Y, Cen H, Zhang M, Wen P . Decreased SOCS1 mRNA expression levels in peripheral blood mononuclear cells from patients with systemic lupus erythematosus in a Chinese population. Clin Exp Med. 2014; 15(3):261-7. DOI: 10.1007/s10238-014-0309-2. View

11.

Liau N, Laktyushin A, Lucet I, Murphy J, Yao S, Whitlock E . The molecular basis of JAK/STAT inhibition by SOCS1. Nat Commun. 2018; 9(1):1558. PMC: 5908791. DOI: 10.1038/s41467-018-04013-1. View

12.

Turnley A, Starr R, Bartlett P . SOCS1 regulates interferon-gamma mediated sensory neuron survival. Neuroreport. 2001; 12(16):3443-5. DOI: 10.1097/00001756-200111160-00013. View

13.

Shao N, Ma G, Zhang J, Zhu W . miR-221-5p enhances cell proliferation and metastasis through post-transcriptional regulation of SOCS1 in human prostate cancer. BMC Urol. 2018; 18(1):14. PMC: 5836432. DOI: 10.1186/s12894-018-0325-8. View

14.

Shao F, Pang X, Baeg G . Targeting the JAK/STAT Signaling Pathway for Breast Cancer. Curr Med Chem. 2020; 28(25):5137-5151. DOI: 10.2174/0929867328666201207202012. View

15.

Hu X, Li J, Fu M, Zhao X, Wang W . The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021; 6(1):402. PMC: 8617206. DOI: 10.1038/s41392-021-00791-1. View

16.

Slattery M, Lundgreen A, Hines L, Torres-Mejia G, Wolff R, Stern M . Genetic variation in the JAK/STAT/SOCS signaling pathway influences breast cancer-specific mortality through interaction with cigarette smoking and use of aspirin/NSAIDs: the Breast Cancer Health Disparities Study. Breast Cancer Res Treat. 2014; 147(1):145-58. PMC: 4167366. DOI: 10.1007/s10549-014-3071-y. View

17.

Heys S, Stewart K, McKenzie E, Miller I, Wong S, Sellar G . Characterisation of tumour-infiltrating macrophages: impact on response and survival in patients receiving primary chemotherapy for breast cancer. Breast Cancer Res Treat. 2012; 135(2):539-48. DOI: 10.1007/s10549-012-2190-6. View

18.

Mellert K, Martin M, Lennerz J, Ludeke M, Staiger A, Kreuz M . The impact of SOCS1 mutations in diffuse large B-cell lymphoma. Br J Haematol. 2019; 187(5):627-637. PMC: 6899586. DOI: 10.1111/bjh.16147. View

19.

Liu Z, Filip I, Gomez K, Engelbrecht D, Meer S, Lalloo P . Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway. Blood Cancer Discov. 2020; 1(1):112-125. PMC: 7679070. DOI: 10.1158/2643-3230.BCD-20-0051. View

20.

Duns G, Vigano E, Ennishi D, Sarkozy C, Hung S, Chavez E . Characterization of DLBCL with a PMBL gene expression signature. Blood. 2021; 138(2):136-148. DOI: 10.1182/blood.2020007683. View